Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL64156 | 0.82 | GPR3 (0.41) | GPR3KCNH2ACHE | |
| Trifluoromethanesulfonic Acid SCHEMBL4620918 | 0.78 | ALDH1A1 (0.35) | GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL5571529 | 0.76 | GPR3 (0.32) | GPR3KCNH2ACHE | |
| Benzimidazole SCHEMBL3403941 | 0.72 | GPR3 (0.36) | GPR3KCNH2 | |
| SCHEMBL8715817 | 0.70 | CA2 (0.37) | — | |
| Trifluoromethanesulfonic Acid SCHEMBL8717967 | 0.70 | KCNH2 (0.38) | GPR3KCNH2ACHE | |
| Trifluoromethanesulfonic Acid SCHEMBL9686740 | 0.69 | KCNH2 (0.44) | GPR3KCNH2ACHE | |
| SCHEMBL8715820 | 0.69 | CA2 (0.34) | — | |
| Trifluoromethanesulfonic Acid SCHEMBL4744382 | 0.67 | — | — | |
| Pyrazole SCHEMBL31717932 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2882715-B1 | PYRAZOLE DERIVATIVES AND THEIR USE AS LPAR5 ANTAGONISTS | SANOFI SA (FR) | 2016-11-09 | — | — | EP | disclosed |
| US-9346762-B2 | Pyrazole derivatives and their use as LPAR5 antagonists | SANOFI (FR) | 2016-05-24 | — | — | US | disclosed |
| EP-2882715-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS LPAR5 ANTAGONISTS | SANOFI (FR) | 2015-06-17 | — | — | EP | disclosed |
| US-20150141477-A1 | Pyrazole Derivatives And Their Use As LPAR5 Antagonists | SANOFI (FR) | 2015-05-21 | — | — | US | disclosed |
| US-8598179-B2 | Pyrazole-carboxamide derivatives as P2Y12 antagonists | SANOFI (FR) | 2013-12-03 | — | — | US | disclosed |
| WO-2013171317-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS LPAR5 ANTAGONISTS | SANOFI (FR) | 2013-11-21 | — | — | WO | disclosed |
| US-8426420-B2 | Heterocyclic pyrazole-carboxamidesas P2Y12 antagonists | SANOFI (FR) | 2013-04-23 | — | — | US | disclosed |
| EP-2238128-B1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFI SA (FR) | 2012-08-22 | — | — | EP | disclosed |
| EP-2238127-B1 | PYRAZOLE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI SA (FR) | 2012-08-15 | — | — | EP | disclosed |
| US-7910606-B2 | Pyrazole-derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-03-22 | — | — | US | disclosed |
| EP-1581523-B1 | PYRAZOLE-DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-09-30 | — | — | EP | disclosed |
| WO-2009080226-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFIS-AVENTIS (FR) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080227-A2 | PYRAZOLE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2009-07-02 | — | — | WO | disclosed |
| US-20080306056-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| US-7429581-B2 | Pyrazole-derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-09-30 | — | — | US | disclosed |
| EP-1581523-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2005-10-05 | — | — | EP | disclosed |
| EP-1479678-A1 | Pyrazole-derivatives as factor xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | disclosed |
| US-20040204406-A1 | Pyrazole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-14 | — | — | US | disclosed |
| WO-2004056815-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-08 | — | — | WO | disclosed |
| EP-1433788-A1 | Pyrazole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306056-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | F12, F5, F11 | GPR3 2263/4885KCNH2 532/4885ACHE 822/4885 |
| US-20040204406-A1 | Pyrazole-derivatives as factor Xa inhibitors | F11, F5, F12 | GPR3 1977/4885KCNH2 481/4885ACHE 2305/4885 |
| US-20150141477-A1 | Pyrazole Derivatives And Their Use As LPAR5 Antagonists | LPAR5, LPAR3, LPAR1 | GPR3 16/4885KCNH2 702/4885ACHE 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.